Abstract
The authors review the present state of knowledge related to neurobiological principles of clinical application of antagonists of excitatory amino acids. Despite of the fact that at present this class of drugs is not widely used in the therapy of the neurologic and psychiatric disturbances, there is a sound theoretical background to start clinical trials in Parkinson's disease, epilepsy, neurodegenerative disorders and in the brain ischemia.